TSX runs higher on rate cut expectations
Vor Biopharma Inc. (NASDAQ:VOR), a biotech company with a market capitalization of $257 million, announced several changes to its board of directors this week, according to a statement released Wednesday based on a recent SEC filing. According to InvestingPro analysis, the company’s stock has delivered an impressive 133% return over the past year, though it currently trades below its Fair Value.
On Monday, Joshua Resnick, M.D., resigned from the board, effective immediately. The company stated that Dr. Resnick’s resignation was not due to any disagreement with Vor Biopharma . On Tuesday, Matthew Patterson and David Lubner also resigned as directors, effective immediately. The company indicated that neither resignation was related to any disagreement with the company.
The board expressed appreciation for the departing directors’ years of leadership and service to Vor Biopharma.
On Wednesday, the board appointed Sarah Reed to fill the vacancy created by Dr. Resnick’s departure. Ms. Reed will serve as an independent Class II director until the company’s 2026 annual meeting of stockholders or until her successor is elected and qualified.
Sarah Reed, age 61, is currently General Counsel of RA Capital Management, L.P., a position she has held since 2019. She is also an adjunct professor of law at Harvard Law School and serves on the Board of Trustees of the Harvard Yenching Institute. Ms. Reed holds a BA with honors from Harvard College and a JD with honors from Harvard Law School.
In connection with her service as a director, Ms. Reed will receive Vor Biopharma’s standard non-employee director compensation, which includes a $40,000 annual cash retainer, payable quarterly and pro-rated for the current quarter. She will also receive stock options to purchase 60,000 shares of the company’s common stock upon appointment and will be eligible for additional options to purchase 30,000 shares at each annual stockholder meeting, starting in 2026.
Ms. Reed was nominated by RA Capital under the terms of a securities purchase agreement dated December 26, 2024. RA Capital and its affiliates currently own over 5% of the company’s voting stock.
The information in this article is based on a press release statement and the company’s SEC filing.
In other recent news, Vor Biopharma announced that its collaborator, RemeGen Co., Ltd., successfully reached the primary endpoint in a Phase 3 clinical study for telitacicept in adults with IgA nephropathy in China. The study demonstrated a significant 55% reduction in the 24-hour urine protein-to-creatinine ratio at 39 weeks compared to a placebo. Additionally, Vor Biopharma’s shareholders approved changes to the company’s 2021 Equity Incentive Plan, increasing the number of shares reserved for issuance by 25 million and adjusting the annual automatic increase in the share reserve.
In leadership developments, Vor Biopharma appointed Alexander Cumbo and Michel Detheux to its Board of Directors, with their roles effective from July 2025. Furthermore, Qing Zuraw has been appointed as Chief Development Officer, bringing extensive experience in clinical development for autoimmune diseases. These recent developments highlight Vor Biopharma’s ongoing strategic initiatives and collaborations in the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.